In the last trading session, 1.02 million Regenxbio Inc (NASDAQ:RGNX) shares changed hands as the company’s beta touched 1.21. With the company’s per share price at $10.21 changed hands at -$0.28 or -2.67% during last session, the market valuation stood at $504.58M. RGNX’s last price was a discount, traded about -182.08% off its 52-week high of $28.80. The share price had its 52-week low at $10.14, which suggests the last value was 0.69% up since then. When we look at Regenxbio Inc’s average trading volume, we note the 10-day average is 0.73 million shares, with the 3-month average coming to 505.64K.
Analysts gave the Regenxbio Inc (RGNX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.22. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RGNX as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Regenxbio Inc (NASDAQ:RGNX) trade information
Instantly RGNX was in red as seen at the end of in last trading. With action -8.92%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -43.12%, with the 5-day performance at -8.92% in the red. However, in the 30-day time frame, Regenxbio Inc (NASDAQ:RGNX) is -16.45% down. Looking at the short shares, we see there were 6.2 million shares sold at short interest cover period of 17.35 days.
The consensus price target for the stock as assigned by Wall Street analysts is 38.5, meaning bulls need an upside of 73.48% from its current market value. According to analyst projections, RGNX’s forecast low is 35 with 40 as the target high. To hit the forecast high, the stock’s price needs a -291.77% plunge from its current level, while the stock would need to soar -242.8% for it to hit the projected low.
Regenxbio Inc (RGNX) estimates and forecasts
Data shows that the Regenxbio Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -49.68% over the past 6 months, a 22.59% in annual growth rate that is considerably higher than the industry average of 17.80%.
The 2024 estimates are for Regenxbio Inc earnings to increase by 24.86%, but the outlook for the next 5-year period is at 13.60% per year.
RGNX Dividends
Regenxbio Inc is expected to release its next quarterly earnings report in November.
Regenxbio Inc (NASDAQ:RGNX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 7.41% of Regenxbio Inc shares while 92.35% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 99.74%. There are 92.35% institutions holding the Regenxbio Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 18.8252% of the shares, roughly 8.61 million RGNX shares worth $100.73 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 11.1818% or 5.11 million shares worth $59.83 million as of 2024-06-30.
